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of guidelines recommended standardized regimenTo the editor,
Since the revival of the National Tuberculosis Control
Program (NTP) in 2001, Pakistan has made remarkable pro-
gress regarding tuberculosis (TB) case notification and treat-
ment success rates. Estimates of the case detection rate for
new and relapse cases has been increased from 2.8% (95%
CI: 2.4–3.5) in 2000 to 58% (95% CI: 44–78) in 2013. Treatment
success rate of TB has been increased from 74% in 4100
treated patients in 2000 to 91% in 111,000 treated cases in
2012 in the country. But the high incidence and prevalence
of drug-resistant TB in the country poses a significant threat
to TB control. Unfortunately, despite the remarkable progress,
Pakistan still ranks the fourth highest multidrug-resistant TB
(MDR-TB) burden country globally [1]. In addition, the high
prevalence and increasing trend of fluoroquinolone-resistant
Mycobacterium tuberculosis (MTB) strains in MDR-TB patients in
the country (17.4% in 2005, 42.9% in 2009 and 53.9% in 2014) is
worsening the issue further [2–4]. Fluoroquinolones make up
the backbone of the MDR-TB treatment regimen. Resistance
to fluoroquinolones has been widely reported as a predictor
of poor treatment outcomes in MDR-TB patients [5].
According to Pakistani national guidelines for management
of drug-resistant TB [6], MDR-TB patients in the intensive
phase should be treated with at least four likely effective
second-line anti-TB drugs (SLD) plus pyrazinamide. In
compliance with national guidelines, treatment in MDR-TB
patients without documented history of previous use of
fluoroquinolones in the country is initiated with a standard-
ized regimen: amikacin/kanamycin-levofloxacin-ethion-
amide-cycloserin/para-amino salicylic acid-pyrazinamide
(Am/km-Lfx-Eto-Cs/PAS-Z). The high prevalence of fluoro-
quinolone resistance in MDR-TB patients observed in the
country questions the appropriateness of the guideline’s
recommended standardized regimen. Initiation treatment
with the standardized regimen (Am/km-Lfx-Eto-Cs/PAS-Z) in
settings of high prevalence of fluoroquinolone resistance
leaves a high proportion of patients with a suboptimal
regimen (<4 likely effective SLD) until the availability of drugsusceptibility testing results, which by conventional methods
usually takes 6–8 weeks. This delay in initiating the optimal
regimen may result in poor treatment outcomes, amplifica-
tion of further resistance, conversion of MDR-TB to exten-
sively drug-resistant TB (XDR-TB) and its transmission in
the community. It is suggested that the NTP should evaluate
MDR-TB patients’ countrywide data for fluoroquinolone
resistance. If finding a high prevalence of fluoroquinolone
resistance is confirmed, then the World Health Organization
(WHO) updated recommended regimen (Am/Cm-Lfx-Eto-
Cs-PAS-Z) [7] for initiating treatment in MDR-TB patients in
settings of high SLD resistance should be adopted to produce
the best possible treatment outcomes and prevent further
amplification of drug resistance. Adoption of more restrictive
policies to control over-the-counter availability of fluoro-
quinolones and their rational use by clinicians are urgently
needed to prevent the further increase in fluoroquinolone-
resistant MTB strains.
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